Adam Walker is a Director in CMC Regulatory Affairs at GSK. After receiving a PhD in Cell Biology from the University of Cambridge, he joined Domantis Limited, a Biotechnology company based on human antibody fragment technology developed in the University Cambridge LMB, leading preclinical discovery programmes. Following the acquisition of Domantis by GSK, he led the microbial and mammalian fermentation and downstream purification functions in GSK’s Innovative Biopharmaceuticals Discovery Unit. After roles in GSK’s clinical development organisation Adam moved to a role in Global Regulatory Affairs, and has led the Cell and Gene Therapy function within CMC Regulatory Affairs since 2018.